TherapeuticsMD (NASDAQ:TXMD) Now Covered by StockNews.com

Equities research analysts at StockNews.com initiated coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a research report issued to clients and investors on Wednesday. The brokerage set a “hold” rating on the stock.

TherapeuticsMD Stock Up 0.7 %

Shares of TXMD stock opened at $1.40 on Wednesday. The stock has a 50-day moving average of $1.56 and a 200-day moving average of $1.75. TherapeuticsMD has a one year low of $1.15 and a one year high of $2.99.

Institutional Investors Weigh In On TherapeuticsMD

A hedge fund recently raised its stake in TherapeuticsMD stock. Clearline Capital LP increased its holdings in shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) by 18.9% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 636,622 shares of the company’s stock after buying an additional 101,282 shares during the quarter. Clearline Capital LP owned 5.52% of TherapeuticsMD worth $1,025,000 as of its most recent SEC filing. Institutional investors and hedge funds own 30.74% of the company’s stock.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.